Akums Drugs & Pharma received an environmental, social, and governance (ESG) rating of 65 for FY26 from NSE Sustainability Ratings & Analytics Limited on September 2, 2026.

The company disclosed the development in a filing with the National Stock Exchange of India Ltd. and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated July 11, 2023, which was updated on January 30, 2026.

Rating Methodology

NSE Sustainability, a subsidiary of NSE Indices Limited and a registered ESG Rating Provider, assigned the score voluntarily. Akums Drugs confirmed it did not engage the agency for this assessment. The rating was derived solely from publicly available information.

The filing notes that the rating link is available via the NSE ESG Rating platform. Dharamvir Malik, Company Secretary & Compliance Officer, signed the intimation on September 3, 2026.

Akums Drugs & Pharmaceuticals will participate in an investor and analysts meet scheduled for September 2, 2026. The event forms part of the Ashwamedh – Elara India Dialogue 2026 series.

The company confirmed the schedule in a disclosure filed with stock exchanges on August 25, 2026. The meet is set for 2:00 pm at the Hyatt in Santacruz East, Mumbai. It will be conducted as a physical group session.

Event Details

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Akums stated that no unpublished price-sensitive information would be shared during the session.

Dharamvir Malik, Company Secretary and Compliance Officer, signed the intimation. The company noted that the schedule remains subject to change based on exigencies from either the investors or the firm.